Literature DB >> 25196387

Gene Therapies for Cancer: Strategies, Challenges and Successes.

Swadesh K Das1,2,3, Mitchell E Menezes1, Shilpa Bhatia1, Xiang-Yang Wang1,2,3, Luni Emdad1,2,3, Devanand Sarkar1,2,3, Paul B Fisher1,2,3.   

Abstract

Gene therapy, which involves replacement of a defective gene with a functional, healthy copy of that gene, is a potentially beneficial cancer treatment approach particularly over chemotherapy, which often lacks selectivity and can cause non-specific toxicity. Despite significant progress pre-clinically with respect to both enhanced targeting and expression in a tumor-selective manner several hurdles still prevent success in the clinic, including non-specific expression, low-efficiency delivery and biosafety. Various innovative genetic approaches are under development to reconstruct vectors/transgenes to make them safer and more effective. Utilizing cutting-edge delivery technologies, gene expression can now be targeted in a tissue- and organ-specific manner. With these advances, gene therapy is poised to become amenable for routine cancer therapy with potential to elevate this methodology as a first line therapy for neoplastic diseases. This review discusses recent advances in gene therapy and their impact on a pre-clinical and clinical level.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2015        PMID: 25196387      PMCID: PMC4363073          DOI: 10.1002/jcp.24791

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  187 in total

Review 1.  Gutless adenovirus: last-generation adenovirus for gene therapy.

Authors:  R Alba; A Bosch; M Chillon
Journal:  Gene Ther       Date:  2005-10       Impact factor: 5.250

2.  Ultrasound guided site specific gene delivery system using adenoviral vectors and commercial ultrasound contrast agents.

Authors:  Candace M Howard; Flemming Forsberg; Corrado Minimo; Ji-Bin Liu; Daniel A Merton; Pier Paolo Claudio
Journal:  J Cell Physiol       Date:  2006-11       Impact factor: 6.384

Review 3.  MDA-7/IL-24: novel cancer growth suppressing and apoptosis inducing cytokine.

Authors:  Moira Sauane; Rahul V Gopalkrishnan; Devanand Sarkar; Zao Zhong Su; Irina V Lebedeva; Paul Dent; Sidney Pestka; Paul B Fisher
Journal:  Cytokine Growth Factor Rev       Date:  2003-02       Impact factor: 7.638

Review 4.  Chapter two--Adenovirus strategies for tissue-specific targeting.

Authors:  Matthew S Beatty; David T Curiel
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

Review 5.  mda-7/IL-24: exploiting cancer's Achilles' heel.

Authors:  Irina V Lebedeva; Moira Sauane; Rahul V Gopalkrishnan; Devanand Sarkar; Zhao-Zhong Su; Pankaj Gupta; John Nemunaitis; Casey Cunningham; Adly Yacoub; Paul Dent; Paul B Fisher
Journal:  Mol Ther       Date:  2005-01       Impact factor: 11.454

6.  Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy.

Authors:  Yasutomo Nasu; Takashi Saika; Shin Ebara; Nobuyuki Kusaka; Haruki Kaku; Fernando Abarzua; Daisuke Manabe; Timothy C Thompson; Hiromi Kumon
Journal:  Mol Ther       Date:  2007-02-27       Impact factor: 11.454

7.  Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.

Authors:  John Irving; Zhuo Wang; Sandra Powell; Chris O'Sullivan; Michael Mok; Brian Murphy; Lisa Cardoza; Jane S Lebkowski; Anish S Majumdar
Journal:  Cancer Gene Ther       Date:  2004-03       Impact factor: 5.987

8.  Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells.

Authors:  S Nayak; O Cao; B E Hoffman; M Cooper; S Zhou; M A Atkinson; R W Herzog
Journal:  J Thromb Haemost       Date:  2009-07-06       Impact factor: 5.824

9.  Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene.

Authors:  G Matlashewski; P Lamb; D Pim; J Peacock; L Crawford; S Benchimol
Journal:  EMBO J       Date:  1984-12-20       Impact factor: 11.598

10.  Soluble CD59 expressed from an adenovirus in vivo is a potent inhibitor of complement deposition on murine liver vascular endothelium.

Authors:  Jarel Gandhi; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

View more
  45 in total

1.  Targeted gene therapy of the HSV-TK/hIL-12 fusion gene controlled by the hSLPI gene promoter of human non-small cell lung cancer in vitro.

Authors:  Shuhong Hao; Xiaoyuan Du; Yang Song; Ming Ren; Qiwei Yang; Ao Wang; Qingyu Wang; Haiyue Zhao; Zhenwu Du; Guizhen Zhang
Journal:  Oncol Lett       Date:  2018-03-01       Impact factor: 2.967

Review 2.  Virotherapy: cancer gene therapy at last?

Authors:  Alan E Bilsland; Pavlina Spiliopoulou; T R Jeffry Evans
Journal:  F1000Res       Date:  2016-08-30

3.  A Universal GSH-Responsive Nanoplatform for the Delivery of DNA, mRNA, and Cas9/sgRNA Ribonucleoprotein.

Authors:  Guojun Chen; Ben Ma; Yuyuan Wang; Shaoqin Gong
Journal:  ACS Appl Mater Interfaces       Date:  2018-05-25       Impact factor: 9.229

4.  Xenobiotic Response Elements (XREs) from Human CYP1A1 Gene Enhance the hTERT Promoter Activity.

Authors:  M V Shepelev; S V Kalinichenko; E K Saakian; I V Korobko
Journal:  Dokl Biochem Biophys       Date:  2019-06-14       Impact factor: 0.788

Review 5.  Nanomaterial-Enabled Cancer Therapy.

Authors:  Sabina Quader; Kazunori Kataoka
Journal:  Mol Ther       Date:  2017-05-19       Impact factor: 11.454

6.  Fatty Acid Synthase (FASN) siRNA-Encapsulated-Her-2 Targeted Fab'-Immunoliposomes for Gene Silencing in Breast Cancer Cells.

Authors:  Arif Khan; Masood A Khan; Ahmed N Aljarbou; Yousef H Aldebasi; Khaled S Allemailem; Mohammed A Alsahli; Shamshir Khan; Abdulmohsen M Alruwetei
Journal:  Int J Nanomedicine       Date:  2020-08-05

Review 7.  Use of Cyclodextrins in Anticancer Photodynamic Therapy Treatment.

Authors:  Amina Ben Mihoub; Ludivine Larue; Albert Moussaron; Zahraa Youssef; Ludovic Colombeau; Francis Baros; Céline Frochot; Régis Vanderesse; Samir Acherar
Journal:  Molecules       Date:  2018-08-02       Impact factor: 4.411

Review 8.  The Development of Next-generation PBMC Humanized Mice for Preclinical Investigation of Cancer Immunotherapeutic Agents.

Authors:  Y Maurice Morillon; Ariana Sabzevari; Jeffrey Schlom; John W Greiner
Journal:  Anticancer Res       Date:  2020-10       Impact factor: 2.480

9.  M3RNA Drives Targeted Gene Delivery in Acute Myocardial Infarction.

Authors:  Raman Deep Singh; Matthew L Hillestad; Christopher Livia; Mark Li; Alexey E Alekseev; Tyra A Witt; Paul G Stalboerger; Satsuki Yamada; Andre Terzic; Atta Behfar
Journal:  Tissue Eng Part A       Date:  2018-09-21       Impact factor: 3.845

Review 10.  Detecting Tumor Metastases: The Road to Therapy Starts Here.

Authors:  M E Menezes; S K Das; I Minn; L Emdad; X-Y Wang; D Sarkar; M G Pomper; P B Fisher
Journal:  Adv Cancer Res       Date:  2016-08-17       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.